SELLAS Life Sciences Group, Inc. (SLS): Total Assets
$78.34M
As of 2025-12-31
$145.38M
As of 2026-06-30
+55.2%
3-year compound annual growth
+11.2%
5-year compound annual growth
-0.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $78.34M | +303.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $19.43M | +212.5% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $6.22M | -70.3% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $20.94M | -20.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $26.27M | -42.9% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $46.05M | +177.3% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $16.61M | -1.8% | 2021-03-23, Balance as of period end |
| 2018-12-31 | $16.91M | -49.5% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $33.53M | +422.2% | 2019-03-22, Balance as of period end |
| 2016-12-31 | $6.42M | -92.2% | 2018-04-13, Balance as of period end |
| 2015-12-31 | $82.14M | +2.1% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $80.49M | -8.5% | 2016-04-15, Balance as of period end |
| 2013-12-31 | $87.98M | +60.0% | 2015-03-05, Balance as of period end |
| 2012-12-31 | $54.99M | +77.6% | 2014-03-17, Balance as of period end |
| 2011-12-31 | $30.97M | +314.2% | 2013-03-12, Balance as of period end |
| 2010-12-31 | $7.48M | n/a | 2012-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 2025-12-31 | $78.34M | +303.2% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $81.29M | +204.1% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $74.31M | -34.4% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $84.18M | -19.7% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $72.06M | -31.1% |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $86.15M | +146.5% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $71.12M | +3.2% |
Compare SLS, ADAG, CPIX, NWBO side by side · Screen every company in Pharmaceutical Preparations ↗